Essential Thrombocythemia
📧 Sign up to get email alerts when something new happens for Essential Thrombocythemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-29Clinical Trial Update: Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients [Phase 2]
Phase 2 feasibility study evaluating apixaban for thromboprophylaxis in patients with JAK2-positive myeloproliferative neoplasms (including …
-
FDA approval · 2024-05-09FDA Approved: ANAGRELIDE — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for ANAGRELIDE submitted by Chartwell RX, LLC. This concerns a generic version of ANAGRELIDE.
-
CLINICAL_TRIALS research · 2024-05-03Clinical Trial Update: Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition [Phase 1]
A Phase 1 clinical trial at Fox Chase Cancer Center tests the combination of pacritinib and talazoparib in myeloproliferative neoplasms unre…
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia [Phase 2]
Phase 2 trial update evaluating topotecan hydrochloride and carboplatin with or without veliparib for advanced myeloproliferative disorders …
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) [Phase 2]
Phase 2 study of bomedemstat in essential thrombocythemia has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-01-08Clinical Trial Update: Myeloproliferative Neoplasms: an In-depth Case-control Study
A completed clinical trial examining myeloproliferative neoplasms with results posted; focuses on Polycythemia Vera, Essential Thrombocythem…
-
CLINICAL_TRIALS trial_result · 2023-07-13Clinical Trial Update: Dual Vaccine Trial in Myeloproliferative Neoplasms [Phase 1, Phase 2]
A dual vaccine trial in myeloproliferative neoplasms completed Phase 1/2 testing for polycythemia vera and essential thrombocythemia.
-
CLINICAL_TRIALS trial_result · 2023-02-27Clinical Trial Update: Agrylin Drug Use-Result Survey
Clinical trial update for Agrylin (anagrelide) showing results from a completed study on essential thrombocythemia; results posted.
-
EMA approval · 2023-02-20EMA Authorised: Xagrid (anagrelide) — Takeda Pharmaceuticals International AG Ireland
Anagrelide (Xagrid) has been authorized by EMA for essential thrombocythemia, with Takeda as the marketing authorization holder.
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies [Phase 2]
Phase 2 clinical trial update on shorter course tacrolimus after non-myeloablative conditioning with related donor PBSCT and high-dose postt…
-
CLINICAL_TRIALS trial_result · 2022-04-27Clinical Trial Update: A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms [Phase 3]
A Phase 3 trial comparing low-dose interferon alpha with hydroxyurea in chronic myeloid neoplasms has completed.
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) [Phase 2]
Phase 2 study comparing ruxolitinib to anagrelide in essential thrombocythemia patients resistant to or intolerant of hydroxyurea; the trial…
-
CLINICAL_TRIALS trial_result · 2021-11-04Clinical Trial Update: Arterial Function and Atherosclerosis in Essential Thrombocythemia
A completed clinical trial assessing arterial function and atherosclerosis in patients with essential thrombocythemia.
-
FDA approval · 2021-10-13FDA Approved: AGRYLIN — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for AGRYLIN (anagrelide hydrochloride) from Takeda Pharmaceuticals America, Inc. The action covers c…
-
CLINICAL_TRIALS trial_result · 2021-07-21Clinical Trial Update: Anagre Cap. in Patients With High-Risk Essential Thrombocythemia [Phase 4]
Phase 4 clinical trial update for Anagre Cap. in high-risk essential thrombocythemia has completed.
-
CLINICAL_TRIALS trial_result · 2021-06-29Clinical Trial Update: The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line [Phase 2, Phase 3]
A phase 2/3 trial evaluating ruxolitinib versus best available therapy in high-risk essential thrombocythemia in second-line treatment was t…
-
CLINICAL_TRIALS trial_result · 2021-02-05Clinical Trial Update: Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia [Phase 2]
Phase 2 long-term safety and efficacy update for momelotinib in various myelofibrosis subtypes; study completed with results posted in 2021.
-
FDA label_change · 2020-02-28FDA Approved: AGRYLIN — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approves a supplemental application for AGRYLIN (anagrelide hydrochloride) submitted by Takeda, resulting in changes to the product labe…
-
FDA approval · 2019-12-31FDA Approved: ANAGRELIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for ANAGRELIDE from Chartwell RX, LLC.
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases [Phase 2]
Phase IIa study of HDAC inhibitor ITF2357 in JAK-2 V617F positive myeloproliferative diseases has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2019-05-15Clinical Trial Update: Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation [Phase 2]
Phase 2 clinical trial update evaluating a sympathicomimetic agonist in patients with myeloproliferative neoplasms carrying JAK2 mutations, …
-
FDA label_change · 2018-12-19FDA Approved: AGRYLIN — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for AGRYLIN (anagrelide hydrochloride) submitted by Takeda Pharmaceuticals America, Inc., updati…
-
CLINICAL_TRIALS trial_result · 2018-10-16Clinical Trial Update: Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia [Phase 1]
Phase 1 study of LY573636-sodium in Acute Myeloid Leukemia and Essential Thrombocythemia completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-07-24Clinical Trial Update: Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) [Phase 3]
A Phase 3 randomized trial comparing pegylated interferon alfa-2a to hydroxyurea in high-risk polycythemia vera and high-risk essential thro…
-
CLINICAL_TRIALS trial_result · 2018-04-17Clinical Trial Update: A Study in Myeloproliferative Disorders [Phase 1]
Phase 1 study in myeloproliferative neoplasms has completed, evaluating patients with essential thrombocythemia, polycythemia vera, and prim…